Vero, I didn't recall hearing that exactly. Just to say that they are thinking about IND's in a couple of indications. Wouldn't it be nice to hear more tomorrow. Ashton has some true investors, but I wish he could engage a whole new batch of them. The way we trade doesn't give investors much confidence yet. I'm a holder either way because I believe our day is fast approaching .
What are you talking about here? What news? ........the post approval dip has come and gone.
We're heading north from here. Profits will occur in a year or so.....unless you're trying to pay the
I'm in this camp as well JD. As we all seem to agree how 15' might be an informative and telling year for pSivida, time will tell. I'm sticking around either way just to see it.
Billy, That's old stuff with Forsight, they've not announced any progress on that gig. Time should be an issue for all involved, including pSivida. We'll see. We're either going into the clinic alone with an IND or we're going with a partner. I'm hoping for partnerships galore. You brought up a very good point with Lucentis. It's lost market share to Eylea on dosing frequency alone, not efficacy. So, if that thesis continues for the Bigs then their competitors are looking for a better release profile to compete. But how many companies can deliver biologics without altering the drug characteristics? That's why the pre-clinical data is so important. If we can deliver these biologics well, then everyone will be paying very close attention to pSIvida, and with very good reason.
Billy, No, I don't think that and here's why. The threshold for treating "back of the eye" diseases are close to being reached. Slowly, various companies are on this threshold of this, and the developed world is on the edge of "pricing issues", and soon it will be; who can deliver an effective drug to treat a huge market and for what price? No country now, will dismiss the efficacy and cost of Avastin for back of the eye diseases (DME, AMD). These diseases should be treated without bankrupting the country. Some counties will not pay the higher price ......when they know the cheaper drug will work (Avastin). So, the market "will now consider cost" as a primary issue, noting that other avenue drugs will be available. pSivida has been working with the Durasert platform since Vitrasert, and I've had my doubts about Iluvien (3 CRL's). However, the issues we face as a planet now, was thought of 9 years ago by pSivida. I'm all in. I think Iluvien (3 years release) is going to kick &^%$ all over Ozurdex ( Dexamethasone; 4 month release).When the DME patients on Veg-F therapy become "refractory". they seriously consider long term steroid sustained release. Roche just might eat Lucentis for back of the eye disease, when Avastin is sitting on the same order form.
846.8K as of 11/14. Down 31 K. I just wonder how many covered this week, or will soon. They must hate an uptrend. Not to say they can't send it down again. Wonder if RA shorted on their way out.
JD, Short interest comes out every two weeks. You can go to Nasdaq website and put in a ticker. New number should be out from mid November. If I find anything, I'll post it.
Hey Terry. It' sure does look like Alimera's stars are lining up with pockets full of cash. I must admit, with the Iluvien CRL hangover that we've all had for years, it looks like the market share for the 3 year release implant might surprise everyone, including me. With the Ozurdex implant only lasting 4-5 months, Iluvien stands to take full advantage. Still makes you wonder why the FDA played it the way they did. Also, Medidur for Uveitis stands to benefit as well. Really looking forward to Paul Ashton's web-cast on the 3rd of December, perhaps more on the pipeline.
JD, How do you get a thumbs down for your post? I don't get it. It must be a short that didn't cover 5 days ago. oops. I'm beginning to agree on Iluvien in anticipation of next quarters US launch, it's well known now in the retina doc community. Perhaps by next years end, there will be good rev's for ALIM with pSivida getting their piece. Piggy back this with Medidur initial data, perhaps late in the year. Then there is the ever hopeful Tethadur platform; lot's to look forward to. It will be good to be a pSivida investor this coming year.
The post approval hangover appears to be ending, with steady interest this week. Even after hours the dip was only 100 shares, so we'll see if next week continues the nice move. I'm just a holder of my shares but I do like to see this company get more institutional owners. I'm still in the camp that says we move big in 15' with many catalysts. Bring on the 5 buck level for institutional's coming in. Then maybe we build momentum for years to come. It's about time.
This is "NOT" pSivida! ...for sure. pSivida is sooooooo conservative, they'd never hype anything like that. I checked it out with IR and that is not pSivida. However, Medidur for Uveitis is all pSivida's and it's kickin' &^%.
It belongs completely to pSivida, with no split at all to anyone but the stockholders. The PIII won't even be filled until the first half of 15'. But, the investigator sponsored study revealed very good results with no recurrence of the disease at 12 months. This is the indication that pSivida has been going at for some time with Retisert, now Medidur ( a vastly improved version) and inserted with a 27 gauge needle; 20% smaller than the Iluvien insert. Have a great weekend all.
So, doesn't that mean pSivida got 9.3 Mil to get the ball rolling? And, now that they have some cash, would we anticipate something happening here going forward. Paul Ashton did say in the last CC that they we're going after glaucoma. Could management have been sitting idle until they got the much needed cash? Two quarter's back, pSivida received a 1.5Mil milestone on a Durasert gig. Could this have been something to do with the bioerodible platform, don't know. It may be however that with the coating patents in combination with Tethadur this might be a platform to watch for now. Durasert is gaining a bit of traction; certainly works for Iluvien on a three year basis.
Just so that everyone is on the same page.....
Watertown, MA, USA (June 14, 2011) – Drug delivery company pSivida Corp (NASDAQ: PSDV, ASX: PVA) today announced it amended and restated its Research and Development Agreement with Pfizer Inc. (NYSE: PFE) to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma. The proposed implant is a bioerodible version of pSivida’s proprietary Durasert™ technology system and is designed to be injected into the subconjunctival space of the eye.
Under this revised agreement, Pfizer will make an initial payment of $2.3 million. pSivida will, with technical assistance from Pfizer, have the right to develop the glaucoma product candidate through Phase II clinical trials. At that point, Pfizer may exercise its option for an exclusive, worldwide license to develop and commercialize the product candidate in return for a $20 million payment, double-digit royalty payments on any sales of the product and additional development, regulatory and sales performance milestone payments of up to $146.5 million. If Pfizer does not exercise its option, pSivida will retain the right to develop and commercialize the glaucoma product on its own or with a partner. As part of the amended agreement, pSivida regains all rights to its intellectual property in ophthalmic applications previously included in the original Research and Collaboration Agreement other than that required for the latanoprost implant.
“Pfizer is an excellent partner, and we are pleased to be entering into this new stage of our relationship involving development of a potentially enhanced glaucoma product,” said Dr. Paul Ashton, President and CEO of pSivida. “The $2.3 million payment from Pfizer comes on top of the approximately $7.0 million in R&D support we have already received from Pfizer since we first started our partnership in 2007. We believe that regaining rights to intellectua
Prxl. I read about them too. For Glaxo to be on board already with a license deal says a lot. Sure will be something to keep an eye on as the trial moves forward. It's interesting that they didn't mention biologic delivery in the way they described the technology. I'm sure they'll be touting it, if they indeed can. Good find. It shows the field of drug delivery and the nano structured silicon field growing in attention.